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Abstract We report the molecular characterization of five
human monoclonal antibodies, BAB1^5 (BAB1: IgG1 ; BAB4:
IgG2 ; BAB2, 3, 5: IgG4), with specificity for the major birch
pollen allergen, Bet v 1. BAB1^5 were obtained after immu-
notherapy and contained a high degree of somatic mutations
indicative of an antigen-driven affinity maturation process. While
BAB1 inhibited the binding of patients IgE to Bet v 1, BAB2
increased IgE recognition of Bet v 1, and, even as Escherichia
coli-expressed Fab, augmented Bet v 1-induced immediate type
skin reactions. The demonstration that IgG antibodies can
enhance allergen-induced allergic reactions is likely to explain
the unpredictability of specific immunotherapy.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
How antigen recognition by antibodies of di¡erent isotypes
can result in completely di¡erent e¡ects is exempli¢ed by Type
I allergy, an immune disorder a¡ecting almost 20% of the
population world wide [1,2]. The immediate type symptoms
of Type I allergy (e.g. allergic rhinitis, conjunctivitis, asthma)
result from the recognition of minute amounts of per se in-
nocuous environmental antigens (e.g. proteins from pollen,
mites, animals, fungi) by IgE antibodies and subsequent
high a⁄nity FcO-receptor-mediated activation of allergic e¡ec-
tor cells (e.g. mast cells, basophils) [3]. While the IgE anti-
body-mediated release of biological mediators (e.g. histamine,
leukotrienes) constitutes the immunopathological basis for the
immediate symptoms observed in allergic patients, much less
is known concerning the role of allergen-speci¢c IgG antibod-
ies in atopy.
In 1935 Robert A. Cooke and his colleagues cured allergic
rhinitis by transfusing to an allergic recipient the blood ob-
tained from a patient who had received speci¢c immunother-
apy with ragweed extract [4]. It was later shown that the
transferable factor represents a thermostable antibody which
according to its ability to ‘block’ the skin response to injected
allergen was termed ‘blocking antibody’ [5]. Next it was dem-
onstrated that all of the antibodies that blocked allergen-in-
duced histamine release from human leukocytes belonged to
the IgG isotype [6] and that allergen-speci¢c IgG4 antibody
levels increased during allergen-speci¢c immunotherapy [7].
However, the hypothesis that successful immunotherapy
may be based on the induction of blocking IgG antibodies
was questioned by studies indicating that e⁄cacy does not
always correlate with the induction of allergen-speci¢c IgG
antibodies [8] and there is nowadays great controversy on
the bene¢cial role of IgG in atopy. Moreover, immunotherapy
of allergy may cause not only immune deviations, but also
anergy and deletions [9].
In an e¡ort to analyze allergen-speci¢c IgG antibodies at a
molecular level, to directly compare antigen recognition by
IgE and IgG antibodies, and to study the interference of
IgE and IgG antibodies, we cloned ¢ve human monoclonal
IgG antibodies (BAB1^5) with high a⁄nity for the major
birch pollen allergen Bet v 1 [10]. We chose Bet v 1 as a model
allergen because it is recognized by IgE antibodies of 95% of
tree pollen allergic patients and almost 60% of them react
exclusively to Bet v 1 [11]. It binds most of the tree pollen-
speci¢c IgE antibodies [12] and shares epitopes with the major
allergens present in Fagales (e.g. alder, hazel, hornbeam, oak)
pollen [13] and plant-derived food (fruits, vegetables, spices)
[14]. Recombinant Bet v 1 possesses equal immunological and
biological properties as natural Bet v 1 and has been ex-
pressed and puri¢ed [15]. Lastly, Bet v 1’s three-dimensional
structure has been determined [16] and the expression of re-
combinant Bet v 1 fragments indicates that IgE epitopes of
Bet v 1 belong to the discontinuous/conformational type [17].
Here we report the molecular characterization of ¢ve Bet v
1-speci¢c human monoclonal IgG antibodies, BAB1^5, and
the remarkable property of the antibody BAB2 to enhance
the binding of Bet v 1-speci¢c IgE to Bet v 1. The interaction
of BAB2-Bet v 1-IgE is discussed as a paradigm for a immu-
nomodulatory network, in which binding of one antibody to
its antigen can augment antigen-recognition by disease-elicit-
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ing antibodies of another class and thus can lead to disease
aggravation.
2. Materials and methods
2.1. Biological materials, E. coli strains and plasmids
Pollen from birch, alder, hazel and hornbeam were purchased from
Allergon (Va«linge, Sweden). Plant food (apple, celery, hazelnuts) was
freshly obtained in a local retail store. Birch pollen-allergic patients
and non-allergic individuals were characterized by case history, skin
prick testing and serology using natural as well as recombinant aller-
gens as described [12]. E. coli strain XL1 Blue was purchased from
Stratagene (La Jolla, CA, USA). Plasmid pComb3HSS was provided
by Dr. Carlos F. Barbas, Scripps Research Institute, La Jolla, CA,
USA [18].
The recombinant Bet v 1 utilized in our study is encoded by the
cDNA originally isolated by IgE immunoscreening of a birch pollen
cDNA library [15]. Recombinant Bet v 1 fragments (amino acids (aa)
1^74; aa 75^160) were puri¢ed as described [17]. Recombinant Phl p
2, a major timothy grass pollen allergen which does not share epitopes
with Bet v 1, was expressed and puri¢ed as described [19].
2.2. Isolation and molecular characterization of human Bet v 1-speci¢c
IgG antibodies BAB1^5
Cell lines secreting BAB1^5 Bet v 1-speci¢c IgG antibodies were
established from a birch pollen allergic patient who had received
hyposensitization therapy with natural birch pollen extract as de-
scribed [10]. RNA was isolated from B-cell clones according to a
single step method described [20]. BAB1^5 cDNAs were obtained
by reverse transcription using the Superscript Reverse Transcriptase
kit (BRL, Gaithersburg, MD, USA) and oligo dT12ÿ18 primers (Phar-
macia, Uppsala, Sweden). The cDNAs were used as templates for
PCR ampli¢cation using a PCR ampli¢cation core kit (Perkin Elmer,
Norwalk, CT, USA). For ampli¢cation of the heavy chain fragment-
encoding cDNAs, individual PCRs were carried with primers with
speci¢city for the six di¡erent human VH families in conjunction
with a primer located at the 3P-end of the gamma constant region.
Heavy chain primers: VH1 5P CCC GAA TTC ATG GAC TGG ACC
TGG AGG 3P ; VH2 5P CCC GAA TTC ATG GAC ATA CTT TGT
ACC AC 3P ; VH3 5P CCC GAA TTC ATG GAG TTT GGG CTG
AGC 3P ; VH4 5P CCC GAA TTC ATG AAA CAC CTG TGG TTC
TT 3P ; VH5 5P CCC GAA TTC ATG GGG TCA ACC GCC ATC
CT 3P ; VH6 5P CCC GAA TTC ATG TCT GTC TCC TTC CTC AT
3P Cg 5P AGC TTC CAC CAA GGG CCC ATG GGT CTT 3P.
cDNAs encoding the light chains were ampli¢ed by individual
PCRs with U or V chain primers with speci¢city for the 3P-end in
conjunction with primers complementary to the di¡erent VU and VV
gene families. Light chain primers: VK1 5P CCC GAA TTC ATG
GAC ATG AGG GTC CCC GCT CAG CTC 3P ; VK2 5P CCC
GAA TTC ATG AGG CTC CCT GCT CAG CTC CTG 3P ; VK3
5P CCC GAA TTC ATG GAA ACC CCA GCG CAG 3P ; VK4 5P
CCC GAA TTC ATG GGG TCC CAG GTT CAC CTC 3P ; Ck 5P
GAG AGA GCT CTT TGT GAC GGG CGA GGG CGA GCT
CAG G 3P ; VL1 5P CCC GAA TTC ATG ACC TGC TCC CCT
CTC CT 3P ; VL2 5P CCC GAA TTC ATG GCC TGG GCT CTG
CTG CTC 3P ; VL3a 5P CCC GAA TTC ATG GCC TGG TCT CCT
CTC CTC 3P ; VL3b 5P CCC GAA TTC ATG GCA TGG ATC CCT
CTC CTC 3P ; VL3c 5P CCC GAA TTC ATG GCC TGG ACT CCT
CTC TTT CTG 3P ; Cl 5P GAG AGA GCG GCC GCC TAT GAA
CAT TCT GTA GGG GCC AC 3P. Two PCR products obtained
independently for each of the heavy chain fragments and light chains
were puri¢ed by preparative agarose gel electrophoresis using GELase
(Epicentre, WI, USA) and used as templates for double stranded
DNA sequencing in a 373DNA sequencer with a TaqDyeDeoxy Ter-
minator Cycle Sequencing kit (Applied Biosystems, Foster City, CA,
USA). The BAB DNA and deduced aa sequences were compared with
germline sequences deposited in the V Base Sequence Directors (Tom-
linson et al., MRC Center for Protein Engineering, Cambridge, UK)
using the DNASTAR software (Madison, WI, USA) and were sub-
mitted to GenBank.
2.3. Expression of recombinant BAB2 Fabs in E. coli
RNA was isolated from EBV-transformed human B-cells secreting
BAB2 antibody by lysis of the cells in 4.7 M guanidine isothiocyanate
and subsequent CsCl density centrifugation [21]. The light chain and
heavy chain Fd encoding cDNA was obtained by reverse transcription
and PCR ampli¢cation using the following primer pairs: heavy chain:
5P GCA TGA ACT AGT TGG GGG ACC ATA TTT GGA 3P ; 5P
CGC GGG ATC CCG CAG GTG CAC CTG CTC GAG TCT GG
3P ; light chain: 5P T CCT TCT AGA TTA CTA ACA CTC TCC
CCT GTT GAA GCT CTT TGT GAC GGG CGA ACT C 3P ; 5P
GAA GTT GAG CTC AGT CAG TCT CCA 3P. The cDNAs encod-
ing the light chain and heavy chain fragment were puri¢ed by prep-
arative agarose gel electrophoresis, cut with SacI/XbaI or SpeI/XhoI,
respectively. Puri¢ed fragments were subcloned into plasmid
pComb3HSS to yield plasmid pComb3HBAB2 and transformed
into E. coli XL1 Blue. The sequences of the BAB2 light chain and
heavy chain fragment-encoding cDNAs of one Bet v 1-reactive clone
(clone 28) were con¢rmed by double stranded sequencing. Clone 28,
containing plasmid pComb3HBAB2, was modi¢ed for the production
of soluble BAB2 Fabs by removal of the gene III-containing SpeI/
NheI fragment. E. coli XL1 Blue were transformed with the modi¢ed
pComb3HBAB2 plasmid and induced with IPTG to produce soluble
recombinant BAB2 Fabs in their periplasmic space.
2.4. Antibody, Fab binding assays
Plant extracts (pollen, plant-derived food) were prepared as de-
scribed [14]. Total protein extracts containing natural Bet v 1/Bet v
1-homologous allergens, puri¢ed recombinant Bet v 1 and rBet v 1
halves, each at approximately 5 Wg/cm gel, were separated by SDS^
PAGE [22] and blotted onto nitrocellulose (Schleicher and Schuell,
Dassel, Germany) [23]. Human IgG antibodies were detected with
1:1000 diluted rabbit anti-human IgG antibodies (Dako, Glostrup,
Denmark) and a 1:1000 diluted 125I-labeled donkey anti-rabbit Ig
antiserum (Amersham, Buckinghamshire, UK). The mouse monoclo-
nal antibody (#15) with speci¢city for rBet v 1 (aa 1^74) [24] was
detected with a 1:500 diluted 125I-labeled sheep anti-mouse Ig anti-
serum (Amersham). Human IgE antibodies were detected with 125I-
labeled anti-human IgE antibodies (RAST, Pharmacia, Uppsala, Swe-
den).
E. coli XL1 Blue colonies expressing Bet v 1-reactive BAB2 Fabs
were identi¢ed by ELISA. rBet v 1 was coated to ELISA plates
(Nunc, Roskilde, Denmark) at a concentration of 10 Wg/ml and
blocked as described [12]. Plates were then probed with the periplas-
mic extracts of pComb3HBAB2-transformed bacteria. Bound Bet v 1-
speci¢c recombinant Fabs were detected with an alkaline phospha-
tase-conjugated goat anti-human Ig (Fab)2 antiserum (Sigma, St.
Louis, MO, USA), diluted 1:5000 in TBST-bu¡er (10 mM Tris^HCl
pH 8, 150 mM NaCl, 0.05% v/v Tween 20, 1% BSA). The goat anti-
human Ig (Fab)2 antiserum was also used to demonstrate the binding
of recombinant BAB2 Fabs to nitrocellulose-blotted Bet v 1 and Bet v
1-homologous allergens.
2.5. Modulation of human IgE binding to rBet v 1 by BAB antibodies
and rBAB2 Fabs
200 ng rBet v 1/well were coated to ELISA plates (Nunc) and
blocked as described [12]. In experiments investigating IgE binding
to Bet v 1 depending on the ratios of blocking (BAB1) or enhancing
(BAB2) BAB antibodies, plates were incubated with complete BAB1
or BAB2 antibodies (50 Wg/well) as well as with mixtures consisting of
75% BAB1:25% BAB2, 50% BAB1:50% BAB2 and 25% BAB1:75%
BAB2. The e¡ect of rBAB2 Fabs on human IgE binding to rBet v 1
was studied by incubating plates with periplasmic extracts of
pComb3HBAB2- or, for comparison, with that of pComb3H-trans-
formed bacteria diluted 1:1 in TBST-bu¡er overnight at 4‡C. Plates
were washed and incubated with 1:5 in TBST-bu¡er diluted sera from
Bet v 1 allergic patients and, for control purposes, with serum from an
atopic individual without Bet v 1-speci¢c IgE, with serum from a non-
atopic individual or with bu¡er alone. Bound serum IgE was detected
with an 1:1000 diluted alkaline phosphatase-conjugated mouse mono-
clonal anti-human IgE antibody (Pharmingen, San Diego, CA, USA).
Results were obtained as mean of duplicate determinations (error of
6 10%) after subtraction of the background (i.e. values obtained with
serum from a non-atopic individual) and were expressed as % of IgE
binding to Bet v 1 without BAB antibodies or as % enhancement of
IgE binding to Bet v 1 (rBAB2 Fabs). Statistical analysis of the data
was performed with two-tailed paired t-tests using Microsoft Excel.
The presence of potential IgE anti-BAB2 immunoreactivity in sera
was also investigated by ELISA. 200 ng/ml of puri¢ed BAB2 anti-
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bodies and, for control purposes, rBet v 1, were coupled to ELISA
plates. Sera were tested for IgE reactivity to plate-bound BAB2 anti-
bodies and rBet v 1 as described above. The successful coupling of
BAB2 antibodies to the ELISA plate was demonstrated with an alka-
line phosphatase-conjugated goat anti-human Ig (Fab)2 antiserum
(Sigma, St. Louis, MO, USA).
2.6. Puri¢cation of recombinant BAB2 Fabs
5 mg of puri¢ed recombinant Bet v 1 were coupled to CNBr-acti-
vated Sepharose 4B (Pharmacia) according to the manufacturer’s in-
structions. The column was stripped with 100 mM Glycin^HCl pH 2.7
and washed with PBS to remove unbound Bet v 1. E. coli extracts
containing recombinant BAB2 Fabs were prepared by homogenizing
cells in PBS and removal of insoluble particles by centrifugation.
After passing the E. coli lysate twice over the Bet v 1 a⁄nity column,
the matrix was washed with PBS until the baseline (OD280 nm) was
reached. Bound BAB2 Fabs were eluted with 100 mM Glycin^HCl
pH 2.7 and immediately neutralized with 3 M Tris^HCl pH 9. The
purity of eluted BAB2 Fabs was con¢rmed by SDS^PAGE and silver-
staining.
2.7. Skin testing
Skin prick tests were performed on the forearms of four birch
pollen allergic and two non-allergic individuals as described [17]. In-
dividuals were pricked with 20 Wl of PBS solution containing either
100 ng or 20 ng of puri¢ed rBet v 1 or rPhl p 2, with or without 2 Wg
of puri¢ed BAB2 Fabs. Birch pollen extract (ALK, Horsholm, Den-
mark), PBS (phosphate bu¡ered saline), and histamine hydrochloride
(ALK) were used as controls. The skin reactions were recorded after
20 min by photography and by determining the wheal surface area as
follows: Surface = [D1+D2)/2]2. D1 represents the maximal longitudi-
nal and D2 the maximal transverse diameter. Statistical analyses of
the BAB2 induced increases of wheal surfaces were performed with
Student’s paired t-test.
3. Results
3.1. BAB1^5 are ¢ve di¡erent human IgG monoclonal
antibodies that recognize di¡erent epitopes of Bet v 1
The sequences of the BAB1^5 heavy and light chains have
been submitted to GenBank under the following accession
numbers: AJ131062: BAB1 hc; AJ131063: BAB1 lc;
AJ131064: BAB2 hc; AJ131055: BAB2 lc; AJ131056:
BAB3 hc; AJ131057: BAB3 lc; AJ131058: BAB4 hc;
AJ131059: BAB4 lc; AJ131060: BAB5 hc; AJ131061:
BAB5 lc. BAB1 belongs to the Q-1 subclass, BAB4 to the
Q-2 subclass and BAB2, 3 and 5 to the Q-4 subclass (Fig. 1;
GenBank). The clonality of the BAB cell lines was con¢rmed
by sequencing VH and VL of two independently obtained
cDNAs. Each of the variable region sequences contained
many somatic mutations (ranging from 13 to 47, average:
23) (data not shown; GenBank). Mutations have preferen-
Fig. 1. Comparison of the BAB2 heavy chain (H) and light chain (L) DNA and aa sequence with their putative germline homologues. The po-
sitions of the complementary determining regions (CDRs) and frameworks (FRs) are indicated. Numbering and CDRs are according to Kabat.
Identical nucleotides or aa are displayed by dashes.
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tially accumulated in CDR1 or CDR2. Sixty nine out of a
total of 196 somatic mutations (34%) were present in the
CDRs which only represented 22% of the total size of the V
fragments, and the ratio of replacement versus silent muta-
tions in CDR1 and CDR2 was high (5.7) compared with that
of the FWRs (1.2). (Fig. 1; GenBank).
BAB3 and BAB4, which are of di¡erent isotype (BAB3:
IgG4 ; BAB4: IgG2), rearranged the same VH2ÿ5 gene with
JH5 and JH1, respectively ([25]; GenBank). BAB3 and
BAB4 heavy chains have recombined with two di¡erent light
chains (BAB3: Vl1e; BAB4: L12A) [26] but shared four iden-
tical replacement mutations in the heavy chain CDRs (Ser-
31aCArg, Met-32CVal, Gly-60CSer, Lys-64CArg) (Gen-
Bank).
All BAB antibodies recognized native [10] as well as re-
combinant Bet v 1 (Fig. 2). Because none of the human mono-
clonal antibodies reacted with synthetic dodecapeptides span-
ning the complete Bet v 1 sequence, the epitopes recognized
by BAB1^5 were determined using the N-terminal (aa 1^74)
and C-terminal (aa 75^160) fragments of Bet v 1 [17]. BAB1
bound strongly to the C-terminal Bet v 1 fragment and
showed a very weak reactivity with the N-terminal fragment,
suggesting that it predominantly recognizes an epitope on the
C-terminal portion of Bet v 1. BAB2 bound strongly and
BAB5 weakly to the N-terminal Bet v 1 fragment but not at
all with the C-terminal fragment. Neither BAB3 nor BAB4
bound to any of the two recombinant Bet v 1 fragments (Fig.
2).
3.2. Recombinant BAB2 Fabs bound to Bet v 1 and
cross-reacted with Bet v 1-homologous allergens in various
pollen and plant-derived food
The cDNAs encoding the BAB2 heavy chain fragment (var-
iable region plus a portion of the ¢rst constant domain) and
Fig. 2. Binding of BAB antibodies to nitrocellulose-blotted recombinant Bet v 1 and recombinant Bet v 1 fragments. rBet v 1, the N-terminal
(rBet v 1 aa 1^74), and the C-terminal (rBet v 1 aa 75^160) Bet v 1 fragment were probed with the BAB antibodies (BAB1^5), a mouse mono-
clonal anti-Bet v 1 antibody (#15) and bu¡er (B).
Table 1
Modulation of IgE binding to Bet v1 after preincubation with BAB antibodies
Patients sera IgE binding after preincubation (%)
100% BAB2 75% BAB2 50% BAB2 25% BAB2 100% BAB1
25% BAB1 50% BAB1 75% BAB1
A 130 114 102 80 51
B 113 108 98 82 71
C 117 104 93 70 41
D 177 154 141 83 23
E 154 146 122 106 58
F 141 146 120 111 70
G 123 123 104 92 57
H 145 144 124 108 51
I 161 144 124 105 38
J 149 143 121 980 45
K 165 147 137 100 35
L 161 143 146 114 37
M 151 145 135 120 56
N 165 150 140 106 33
O 229 235 218 185 91
mean 152 143 128 104 50
Modulation of IgE binding to rBet v 1 depends on the ratios of blocking (BAB1) or enhancing (BAB2) IgG antibodies. ELISA plate-bound
rBet v 1 was preincubated with bu¡er, BAB1 or BAB2 alone, and with mixtures (75% BAB2:25% BAB1; 50% BAB2:50% BAB1;
25%BAB2:75% BAb1) of BAB1 and BAB2. IgE binding of sera from 15 birch pollen allergic patients (patients A^O) is displayed as percentage
binding where 100% represents the IgE binding yielded after allergen preincubation with bu¡er alone. The mean modulation of IgE binding is
displayed in the bottom line.
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the complete BAB2 light chain (Fig. 1) were co-expressed as
pComb3HBAB2 construct. The assembly of the recombinant
heavy chain fragment and light chain is con¢rmed by our
¢nding that under non-reducing conditions, puri¢ed recombi-
nant BAB2 Fabs migrate as disulphide bond-linked hetero-
dimers at approximately 60 kDa in SDS^PAGE (Fig. 3A;
lanes 2: silverstain, K-hu Fab). Both chains are disrupted
under reducing conditions and thus appear as double band
of approximately 26^27 kDa (Fig. 3A; lane 1: K-hu Fab).
The binding of recombinant BAB2 Fabs and complete nat-
ural antibodies to ELISA plate-bound rBet v 1 were com-
pared at di¡erent antibody/Fab dilutions (Fig. 3B). The sim-
ilar shape of the binding curves recorded for the di¡erent
antibody/Fab dilutions suggests a comparable ability of com-
plete BAB2 antibodies and rBAB2 Fabs to bind to rBet v 1.
Furthermore, like serum IgE from Bet v 1 allergic patients,
rBAB2 Fabs cross-reacted identically with Bet v 1-homolo-
gous allergens present in various tree pollen (hornbeam, hazel,
alder) as well as in plant-derived food (celery, apple, hazelnut)
(Fig. 3C).
3.3. BAB1 inhibits the binding of IgE from atopic patients to
Bet v 1 while BAB2 enhances it
Using an ELISA assay we found that BAB3, 4 and 5 had
no signi¢cant in£uence on IgE binding to Bet v 1. In contrast,
BAB1 strongly inhibited the binding of IgE in 15/15 atopic
sera (P = 4.9U1036) (Table 1). On the other hand, BAB2
stimulated the binding of IgE to Bet v 1 in 15/15 atopic
sera (P = 6U1036) (Table 1). Both antibodies antagonized
each other, however the BAB2 enhancing activity seemed to
dominate over the inhibitory capacity of BAB1 because pre-
incubation of Bet v 1 with an equimolar mixture of both
antibodies enhanced IgE binding in 13 out of 15 sera (mean
binding 128%) and even a ratio of 25% BAB2:75% BAB1 was
su⁄cient to increase IgE binding to Bet v 1 in 8 out of 15 sera
(Table 1). That the increased IgE reactivity to BAB2-bound
Bet v 1 resulted from the presence of IgE anti-BAB2 immu-
noreactivity is unlikely because no IgE antibodies against pu-
ri¢ed BAB2 antibodies could be detected by ELISA in the
sera (data not shown).
6
Fig. 3. A: E. coli expression and puri¢cation of BAB2 Fabs. Lane 1
shows nitrocellulose-blotted E. coli periplasmic extracts containing
recombinant BAB2 Fabs separated by SDS^PAGE under reducing
conditions. The comigrating recombinant heavy chain fragment and
light chain were detected with a goat anti-human Fab antiserum (K-
hu Fab). Lanes 2 show a⁄nity puri¢ed BAB2 Fabs separated by
SDS^PAGE under non-reducing conditions visualized by silver-
staining (silverstain) and after blotting to nitrocellulose detected by
the goat anti-human Fab antiserum (K-hu Fab). B: Comparison of
the binding of natural BAB2 (white squares) and recombinant
BAB2 Fab clone 28 (¢lled squares) to ELISA plate-bound recombi-
nant Bet v 1. One:two dilutions (x-axis) of natural BAB 2 or re-
combinant BAB2 Fabs were exposed to constant amounts of ELISA
plate-bound rBet v 1. The optical density (OD) values at the y-axis
represent means of duplicate determinations and correspond to the
bound antibodies or rFabs. C: Cross-reactivity of IgE antibodies
from a birch pollen allergic patient (IgE) and recombinant BAB2
Fabs with nitrocellulose-blotted Bet v 1 and Bet v 1-homologous al-
lergens. from alder, hazel, hornbeam, hazelnut, apple and celery.
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3.4. Recombinant BAB2 Fabs enhance IgE binding to Bet v 1
and Bet v 1-induced immediate type skin reactions
Preincubation of rBet v 1 with recombinant BAB2 Fabs
substantially increased IgE binding of all 17 birch pollen al-
lergic patients’ sera to rBet v 1 (Fig. 4A). Five sera showed a
more than 50% and eight sera a 20^50% increase of IgE bind-
ing to Bet v 1. Only four sera showed a lower than 20%
enhancement of IgE binding to Bet v 1. No signi¢cant IgE
binding to Bet v 1 was detected when serum from an atopic
patient without Bet v 1-speci¢c IgE, a non-atopic individual
or bu¡er were tested (data not shown).
Using in vivo skin test experiments, preincubation of rBet v
1 with rBAB2 Fabs augmented the Bet v 1-induced skin re-
actions (wheal area) in all four Bet v 1-allergic patients tested
(Table 2; Fig. 4B). We observed a two-threefold increase of
the Bet v 1-induced wheal area at each of the two di¡erent Bet
v 1 concentrations (wheal areas in Table 2; Fig. 4B). The
results were statistically signi¢cant (P = 0.01) when analyzed
in a Student’s paired t-test. Preincubation of rBet v 1 with
rBAB2 Fabs also enlarged the erythema area in Bet v 1-sen-
sitized patients (Fig. 4B). The speci¢city of the BAB2-induced
increase of skin reactivity was supported by the following
controls:
1. Preincubation of a Bet v 1-unrelated grass pollen allergen,
Phl p 2, with rBAB2 Fabs did not increase rPhl p 2-in-
duced skin reactions (Table 2; Fig. 4B).
2. rBAB2 Fabs alone failed to induce skin reactions in Bet v
1-allergic and in non-allergic individuals (Table 2; Fig. 4B).
3. A mixture of rBAB2 Fabs and rPhl p 2 did not cause
immediate type skin reactions in patients who were not
sensitized to Phl p 2 or in non-allergic individuals (Table
2; Fig. 4B). Additionally, all Bet v 1-allergic patients
mounted immediate type skin reactions to birch pollen ex-
tract and allergic and non-atopic persons presented a wheal
reaction in response to histamine (Table 2; Fig. 4B).
4. Discussion
The role of allergen-speci¢c IgG antibodies in atopy has
been a matter of debate for more than 50 years. Herein, we
report the molecular characterization of ¢ve human IgG
monoclonal antibodies, BAB1^5, with speci¢city for the major
birch pollen allergen, Bet v 1, one of the most frequently
recognized environmental allergens [11]. Three (BAB2,
BAB3, BAB5) of the ¢ve Bet v 1-speci¢c IgG antibodies be-
longed to the IgG4 subclass, what may re£ect either the typ-
ical Th2-biased cytokine environment in allergic patients that
favors isotype switching towards IgE and IgG4 [27] or the
increase of allergen-speci¢c IgG4 antibody levels induced by
immunotherapy [7]. The high frequency of somatic mutations
indicates that the ¢ve BAB antibodies derived from memory
B-cells as previously suggested by these antibodies high a⁄n-
ity [10]. BAB3 (Q4-subclass) and BAB4 (Q2-subclass) rear-
ranged the same VH2ÿ5 gene with JH5 and JH1, respectively,
but expressed di¡erent light chains (VV1e and L12A, respec-
tively), which suggests that the VH2ÿ5 peptide may play an
important role in the contact/binding to Bet v 1.
In contrast to IgE, three out of the ¢ve BAB antibodies
(BAB1, BAB2 and BAB5) were able to bind to the recombi-
nant Bet v 1 halves, indicating that the epitopes recognized by
these BABs are di¡erent from the IgE binding sites. This
¢nding exempli¢es that allergen-speci¢c IgE and IgG antibod-
ies can recognize di¡erent epitopes. When tested for their
ability to in£uence IgE binding to Bet v 1, three of the ¢ve
BAB antibodies (BAB3, 4 and 5) had little or no e¡ect and
only BAB1 blocked IgE anti-Bet v 1 reactivity. This provides
one explanation why immunotherapy does not always lead to
reduction of symptoms: some therapy-induced IgG antibodies
directed to epitopes other than IgE epitopes are unable to
block the IgE-allergen interaction.
Moreover, BAB2, a human IgG4 antibody, was found to
increase the binding of IgE to Bet v 1, and thus can be de¢ned
Table 2
E¡ect of recombinant BAB2 Fabs on Bet v 1-induced immediate type skin reactions
Individual Wheal surface in mm2 after testing with
rBet v 1 rBet v 1 rBet v 1 rBet v 1 rPhl p 2 rPhl p 2 rPhl p 2 rPhl p 2 birch histamine
1 Wg/ml+
PBS
1 Wg/ml+
BAB2
5 Wg/ml+
PBS
5 Wg/ml+
BAB2
1 Wg/ml+
PBS
1 Wg/ml+
BAB2
5 Wg/
ml+PBS
5 Wg/ml+
BAB2
O.S. 6.25 25 12.25 49 0 0 0 0 25 56.25
T.C. 42.25 81 64 289 42.25 36 49 49 52.56 36
S.S. 6.25 36 56.25 81 0 0 0 0 64 30.25
F.S. 12.25 56.25 76.56 110.25 0 0 0 0 45.56 45.56
V.R. 0 0 0 0 0 0 0 0 0 36
E.P. 0 0 0 0 0 0 0 0 0 20.25
In£uence of recombinant BAB2 Fabs on Bet v 1-induced immediate type skin reactions. Individuals in Table 2 correspond to Fig. 4B as fol-
lows: O.S.: A = B, T.C.: C and E.P.: D.
6
Fig. 4. A: Increased IgE recognition of ELISA-plate-bound rBet v 1 after preincubation with rBAB2 Fabs. The percentage enhancement of
IgE binding to rBet v 1 (y-axis) is displayed for sera from 17 birch pollen allergic patients (x-axis). Results represent mean values of duplicate
measurements with an error of 6 10%. B: Enhancement of Bet v 1-induced immediate type skin reactions by recombinant BAB2 Fabs. Two
birch pollen allergic patients (B: A = B, C) and a non-allergic individual (B: D) were skin tested on their forearms with two concentrations of
rBet v 1 and rPhl p 2 mixed with PBS or rBAB2 Fabs, with PBS, rBAB2 Fabs alone, birch pollen extract and histamine. The application order
of the test substances is displayed in the inset. Skin reactions in the ¢rst birch pollen-allergic patient are shown without (B,A) and with (B,B)
surrounding of the wheal area. Wheal areas in individuals C and D are surrounded with a ball point pen (Fig. 4B).
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as an ‘enhancing antibody’. This in vitro ¢nding is further
supported by in vivo studies where rBAB2 Fabs were shown
to increase Bet v 1-induced immediate skin reactions in Bet v
1-allergic patients. The existence of stimulatory anti-allergen
IgG antibodies provides another explanation for the failures
of immunotherapy with respect to the reduction of allergic
symptoms. The balance between ‘stimulatory’ versus ‘block-
ing’ anti-allergen IgG antibodies may thus dictate the out-
come of a course of allergen immunotherapy.
rBAB2 Fabs cannot interfere with allergic e¡ector cells (e.g.
mast cells, basophils [28] because they lack Fc regions. BAB2
Fabs may however display an enhancing activity by directly
exposing IgE epitopes through conformational changes of the
allergen. In line with this hypothesis, IgG antibodies like
BAB2 may directly act on the selection of IgE epitopes during
the early stage of allergen sensitization as IgG-complexed al-
lergens presented on germinal center follicular dendritic cells
(FDCs) may contribute to the positive selection of B-cells
expressing Bet v 1-speci¢c IgE antibodies.
In summary, BAB2 represents an example of a human IgG
antibody whose binding to its antigen further enhances the
binding of anaphylactic IgE and thus contributes to disease
aggravation. Therefore, the analysis of the BAB human
monoclonal IgG antibodies may help to explain the unpredict-
ability of allergen-based immunotherapy and, perhaps, help to
learn how to orient the production of IgG antibodies towards
the blocking type to improve the outcome of speci¢c immu-
notherapy.
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